Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

OBJECTIVE: To report the primary (1‐year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading d...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Blanco, Ricardo, Dokoupilová, Eva, Hall, Stephen, Kameda, Hideto, Kivitz, Alan J., Poddubnyy, Denis, van de Sande, Marleen, Wiksten, Anna S., Porter, Brian O., Richards, Hanno B., Haemmerle, Sibylle, Braun, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839589/
https://www.ncbi.nlm.nih.gov/pubmed/32770640
http://dx.doi.org/10.1002/art.41477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839589/
https://www.ncbi.nlm.nih.gov/pubmed/32770640
http://dx.doi.org/10.1002/art.41477

Ejemplares similares